PDCD1 and melanoma: In a sensitive in vitro model based on expanded autologous tumor-infiltrating lymphocytes (TILs) and melanoma cell lines obtained from tumor specimens of melanoma patients, LAG-3 and PD-1+LAG-3 inhibition promoted antitumor immune responses in human autologous melanoma/T-cell cocultures [58].